Paolo Muraro is a Clinical Reader in Neuroimmunology and is the Deputy Head of Division (Education and Training) of the Division of Brain Sciences, Department of Medicine, Imperial College London, where he heads the Clinical Neuroimmunology Group within the Centre for Neuroinflammation and Neurodegeneration. He is also a Honorary Consultant Neurologist at Imperial College Healthcare NHS Trust.
A medical graduate from University of Rome "La Sapienza", Dr Muraro trained in Clinical Neurology and Neuroimmunology both in Italy and in the United States, where he has been a Senior Research Fellow (Visiting Scientist) at the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke and a Neurologist at the Clinical Center, National Institutes of Health, Bethesda, MD, USA.
His research programme is aimed at understanding and developing effective therapies for inflammatory neurological diseases, particularly multiple sclerosis (MS). His scientific contributions include studies of T cell repertoires in health and autoimmune disorders, and the elucidation of the mechanisms of action of immuno-modulatory treatments and haematopoietic stem cell transplantation (HSCT) in MS.
He has published more than 100 peer-reviewed articles in international scientific journals in addition to a few hundred abstract presentations and a number of book chapters, editorial comments and interviews. His research programme is funded by the Medical Research Council, the UK Multiple Sclerosis Society, the UK Stem Cell Foundation, the Wellcome Trust, and the Italian Multiple Sclerosis Society.
He has received the 2013 Van Bekkum Award, the most prestigious European Blood and Marrow Transplantation (EBMT) award for the best abstract submitted to the physician''s programme.
Dr Muraro is a Member of the UK Multiple Sclerosis Society Grant Review Panel 1 and serves as Scientific Reviewer and Editorial Board member for several scientific journals as well as a referee or chair of review committees for a number of funding Agencies and Charities. He has often been invited to present as Speaker to plenary sessions at international scientific meetings in the fields of MS, neuroimmunology and bone marrow transplantation.
*** PLEASE NOTE: Due to the large number of enquiries received, Dr Muraro regrets he is unable to reply to emails or phone calls from individuals seeking advice on therapies, stem cell treatments or participation in clinical trials. Any clinical trials in which Dr Muraro is involved are published on www.clinicaltrials.gov and the recruitment status and contact information is indicated there. Thank you ***
et al., 2017, Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, Jama Neurology, Vol:74, ISSN:2168-6149, Pages:459-469
et al., 2014, T cell repertoire following autologous stem cell transplantation for multiple sclerosis, Journal of Clinical Investigation, Vol:124, ISSN:0021-9738, Pages:1168-1172
Ali R, Nicholas RSJ, Muraro PA, 2013, Drugs in Development for Relapsing Multiple Sclerosis, Drugs, Vol:73, ISSN:0012-6667, Pages:625-650
et al., 2012, A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper, Multiple Sclerosis Journal, Vol:18, ISSN:1352-4585, Pages:825-834
et al., 2011, Age and disability accumulation in multiple sclerosis, Neurology, Vol:77, ISSN:0028-3878, Pages:1246-1252
et al., 2010, T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+selected graft, Bone Marrow Transplantation, Vol:45, ISSN:0268-3369, Pages:325-331
et al., 2009, Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study, Lancet Neurology, Vol:8, ISSN:1474-4422, Pages:244-253
et al., 2007, Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response, Journal of Neuropathology and Experimental Neurology, Vol:66, ISSN:0022-3069, Pages:637-649
Packer AN, Muraro PA, 2007, Optimized clonotypic analysis of T-cell receptor repertoire in immune reconstitution, Experimental Hematology, Vol:35, ISSN:0301-472X, Pages:516-521
et al., 2006, Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis, Journal of Neuroimmunology, Vol:171, ISSN:0165-5728, Pages:177-183
Muraro PA, Douek DC, 2006, Renewing the T cell repertoire to arrest autoimmune aggression, Trends in Immunology, Vol:27, ISSN:1471-4906, Pages:61-67
et al., 2005, Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients, Journal of Experimental Medicine, Vol:201, ISSN:0022-1007, Pages:805-816
et al., 2004, Decreased integrin gene expression in patients with MS responding to interferon-beta treatment., Journal of Neuroimmunology, Vol:150, ISSN:0165-5728, Pages:123-131
Muraro PA, Ingoni RC, Martin R, 2003, Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges, Current Opinion in Neurology, Vol:16, ISSN:1350-7540, Pages:299-305
et al., 2003, Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders, Brain, Vol:126, ISSN:0006-8950, Pages:20-31
et al., 2002, Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing-remitting MS., Journal of Neuroimmunology, Vol:127, ISSN:0165-5728, Pages:149-159
et al., 2000, Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor V beta analysis, Journal of Immunological Methods, Vol:246, ISSN:0022-1759, Pages:131-143
et al., 2000, VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis, Journal of Neuroimmunology, Vol:111, ISSN:0165-5728, Pages:186-194
et al., 2000, Human autoreactive CD4(+) T cells from naive CD45RA(+) and memory CD45RO(+) subsets differ with respect to epitope specificity and functional antigen avidity, Journal of Immunology, Vol:164, ISSN:0022-1767, Pages:5474-5481
et al., 1997, Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire, Journal of Clinical Investigation, Vol:100, ISSN:0021-9738, Pages:339-349
et al., 2008, Hematopoietic stem cell transplantation for autoimmune disorders, Hematopoietic Stem Cell Transplantation in Clinical Practice, Editor(s): Barrett, Treleaven, Edinburgh, Churchill Livingstone/Elsevier Science, Pages:197-210, ISBN:9780443101472